HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HANXBIO-B

19.160

+0.3601.91%

Volume:474.00K

Turnover:8.98M

Market Cap:2.61B

PE:-20.87

High:19.390

Open:19.390

Low:18.250

Close:18.800

52wk High:29.480

52wk Low:13.480

Shares:136.22M

HK Float Shares:136.22M

Volume Ratio:3.61

T/O Rate:0.35%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.918

ROE:-43.61%

ROA:-13.64%

PB:13.87

PE(LYR):-20.87

PS:1048.21

Loading ...

Overview Company News Filings

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) Announces EGM Poll Results

Bulletin Express

Hanx Biopharmaceuticals (Wuhan) Co. Ltd. held extraordinary general meeting

Hanx Biopharmaceuticals (3378) Announces Board and Committee Composition

Bulletin Express

Hanx Biopharmaceuticals Files Director List with HKEX

Hanx Biopharmaceuticals Enrolls, Doses First Patient in Tumor Drug Trial

MT Newswires Live

Hanx Biopharmaceuticals (3378) Announces First Patient Dosing in HX111 Phase I Clinical Trial

Bulletin Express

HANXBIO-B (03378): First Patient Dosed in HX111 Clinical Trial

HANXBIO-B (03378) Announces Reassignment of Xiao Jieyu from Non-Executive to Executive Director

Hanx Biopharmaceuticals Doses First Patient in Phase I Trial of OX40-Targeted ADC HX111

Hanx Biopharmaceuticals (Wuhan) Co Ltd - Xiao Jieyu Re-Designated as Executive Director

THOMSON REUTERS

Hanx Biopharmaceuticals (Wuhan) - Zhang Hui Resigned as CFO

THOMSON REUTERS

Hanx Biopharmaceuticals Appoints Xiao Jieyu as Executive Director and CFO

Hanx Biopharmaceuticals Proposes General Mandate to Repurchase H Shares at Upcoming EGM

Hanx Biopharmaceuticals (3378) Announces Extraordinary General Meeting Agenda

Bulletin Express

Hanx Biopharmaceuticals (3378) Announces Proposal for H Share Repurchase Mandate

Bulletin Express

HANXBIO-B Announces Conclusion of Stabilization Period, No Stabilization Actions Taken, and Over-Allotment Option Lapses

Hanx Biopharmaceuticals (3378) Announces End of Stabilization Period and Lapse of Over-allotment Option

Bulletin Express

HANXBIO-B (03378): Stabilization Period Concludes, No Price-Stabilizing Actions, and Over-Allotment Option Lapses

Stock Track | HANXBIO-B Plummets 13.46% Intraday Amid Financial Losses and Lack of Commercialized Products

HANXBIO-B (03378) Plummets Over 13%, Halved from IPO Price with Market Cap Around HK$2 Billion

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/03378/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"03378","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03378\",,,,,undefined,":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"HANXBIO-B","latestPrice":19.16,"timestamp":1770970087188,"preClose":18.8,"halted":0,"volume":474000,"delay":0,"changeRate":0.019148936170212735,"floatShares":136218830,"shares":136218830,"eps":-0.918,"marketStatus":"Not Yet Opened","change":0.36,"latestTime":"02-13 16:08:07","open":19.39,"high":19.39,"low":18.25,"amount":8982385,"amplitude":0.060638,"askPrice":19.16,"askSize":300,"bidPrice":19.14,"bidSize":500,"shortable":0,"etf":0,"ttmEps":-1.222,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771205400000},"marketStatusCode":0,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":18.8,"openAndCloseTimeList":[[1770946200000,1770955200000],[1770958800000,1770969600000]],"volumeRatio":3.6062081585561536,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000905","market":"SZ","secType":"STK","nameCN":"Xiamen Port Development Co.,Ltd.","latestPrice":12.22,"timestamp":1770966000000,"preClose":12.23,"halted":0,"volume":8393500,"delay":0,"premium":"+38.47"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03378\",,,,,undefined,":{"symbol":"03378","floatShares":136218830,"roa":"-13.64%","roe":"-43.61%","lyrEps":-0.918,"volumeRatio":3.6062081585561536,"shares":136218830,"dividePrice":0,"high":19.39,"amplitude":0.060638,"preClose":18.8,"low":18.25,"week52Low":13.48,"pbRate":"13.87","psRate":"1048.21","week52High":29.48,"institutionHeld":0,"latestPrice":19.16,"committee":0.25,"eps":-0.918,"divideRate":0,"volume":474000,"delay":0,"ttmEps":-1.222,"open":19.39,"prevYearClose":15.98,"prevWeekClose":19.16,"prevMonthClose":16.95,"prevQuarterClose":15.98,"fiveDayClose":16.1,"twentyDayClose":17.06,"sixtyDayClose":32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03378\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03378\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03378\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/03378\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"03378","date":"2026-02-13","current":-15.679214,"percent":0,"low":-19.892571,"twenty":4.857721,"median":5.514388,"eighty":9.398557,"high":11.401072,"avg":4.75817,"sd":7.474108,"marketCap":2609952782},"quantilePoints":[{"date":"2021-02-19","current":11.141569,"twenty":6.241319,"median":8.855578,"eighty":10.52353,"marketCap":3762156000},{"date":"2021-02-26","current":10.195145,"twenty":6.241319,"median":8.865139,"eighty":10.536788,"marketCap":3435012000},{"date":"2021-03-05","current":10.950823,"twenty":6.24107,"median":8.870518,"eighty":10.569441,"marketCap":3680370000},{"date":"2021-03-12","current":10.482471,"twenty":6.24107,"median":8.877847,"eighty":10.591134,"marketCap":3516798000},{"date":"2021-03-19","current":10.648533,"twenty":6.240821,"median":8.876278,"eighty":10.604656,"marketCap":3571322000},{"date":"2021-03-26","current":10.124223,"twenty":6.24107,"median":8.877847,"eighty":10.605193,"marketCap":3380488000},{"date":"2021-04-01","current":8.974412,"twenty":6.241319,"median":8.879416,"eighty":10.605108,"marketCap":3026082000},{"date":"2021-04-09","current":9.115992,"twenty":6.240821,"median":8.876278,"eighty":10.605277,"marketCap":3080606000},{"date":"2021-04-16","current":9.081606,"twenty":6.240821,"median":8.876278,"eighty":10.605277,"marketCap":3080606000},{"date":"2021-04-23","current":8.898598,"twenty":6.240821,"median":8.870388,"eighty":10.605277,"marketCap":3026082000},{"date":"2021-04-30","current":7.616306,"twenty":6.240821,"median":8.865139,"eighty":10.605277,"marketCap":2998820000},{"date":"2021-05-07","current":8.408393,"twenty":6.240821,"median":8.865139,"eighty":10.605277,"marketCap":2889772000},{"date":"2021-05-14","current":8.572623,"twenty":6.240572,"median":8.870518,"eighty":10.605361,"marketCap":2944296000},{"date":"2021-05-21","current":9.125741,"twenty":6.240515,"median":8.879786,"eighty":10.605492,"marketCap":3135130000},{"date":"2021-05-28","current":7.973288,"twenty":6.240515,"median":8.880182,"eighty":10.605492,"marketCap":3189654000},{"date":"2021-06-04","current":8.148212,"twenty":6.240457,"median":8.880655,"eighty":10.605622,"marketCap":3244178000},{"date":"2021-06-10","current":8.073784,"twenty":6.240515,"median":8.880182,"eighty":10.605492,"marketCap":3216916000},{"date":"2021-06-18","current":7.248909,"twenty":6.2404,"median":8.881129,"eighty":10.605753,"marketCap":2862510000},{"date":"2021-06-25","current":6.977152,"twenty":6.2404,"median":8.881129,"eighty":10.605753,"marketCap":2753462000},{"date":"2021-06-30","current":6.560321,"twenty":6.2404,"median":8.881129,"eighty":10.605753,"marketCap":2589890000},{"date":"2021-07-09","current":6.71929,"twenty":6.240342,"median":8.881945,"eighty":10.605883,"marketCap":2644414000},{"date":"2021-07-16","current":6.511612,"twenty":6.240342,"median":8.881945,"eighty":10.605883,"marketCap":2562628000},{"date":"2021-07-23","current":6.096563,"twenty":6.238278,"median":8.881945,"eighty":10.605883,"marketCap":2399056000},{"date":"2021-07-30","current":5.79996,"twenty":6.233026,"median":8.881945,"eighty":10.605883,"marketCap":2290008000},{"date":"2021-08-06","current":6.090856,"twenty":6.221418,"median":8.881945,"eighty":10.605883,"marketCap":2399056000},{"date":"2021-08-13","current":6.220809,"twenty":6.220848,"median":8.881945,"eighty":10.605883,"marketCap":2453580000},{"date":"2021-08-20","current":5.891906,"twenty":6.215651,"median":8.881129,"eighty":10.606014,"marketCap":2317270000},{"date":"2021-08-27","current":6.211114,"twenty":6.21107,"median":8.882761,"eighty":10.607478,"marketCap":2453580000},{"date":"2021-09-03","current":5.545615,"twenty":6.208353,"median":8.884377,"eighty":10.608943,"marketCap":2453580000},{"date":"2021-09-10","current":5.900149,"twenty":6.193519,"median":8.880182,"eighty":10.608943,"marketCap":2617152000},{"date":"2021-09-17","current":5.547797,"twenty":6.178602,"median":8.879984,"eighty":10.608211,"marketCap":2453580000},{"date":"2021-09-24","current":5.395896,"twenty":6.168457,"median":8.870647,"eighty":10.603497,"marketCap":2371794000},{"date":"2021-09-30","current":5.316083,"twenty":6.15787,"median":8.864959,"eighty":10.580915,"marketCap":2344532000},{"date":"2021-10-08","current":5.316326,"twenty":6.147257,"median":8.853246,"eighty":10.544157,"marketCap":2344532000},{"date":"2021-10-15","current":5.374457,"twenty":6.140429,"median":8.815924,"eighty":10.511884,"marketCap":2371794000},{"date":"2021-10-22","current":5.27481,"twenty":6.127225,"median":8.797247,"eighty":10.493516,"marketCap":2344532000},{"date":"2021-10-29","current":5.349373,"twenty":6.119344,"median":8.779365,"eighty":10.475509,"marketCap":2371794000},{"date":"2021-11-05","current":4.889355,"twenty":6.114079,"median":8.748721,"eighty":10.420921,"marketCap":2208222000},{"date":"2021-11-12","current":4.809165,"twenty":6.108215,"median":8.717377,"eighty":10.3914,"marketCap":2180960000},{"date":"2021-11-19","current":4.876179,"twenty":6.101111,"median":8.695621,"eighty":10.35108,"marketCap":2208222000},{"date":"2021-11-26","current":4.87462,"twenty":6.084623,"median":8.671197,"eighty":10.318496,"marketCap":2208222000},{"date":"2021-12-03","current":5.22604,"twenty":6.078106,"median":8.624866,"eighty":10.2832,"marketCap":2371794000},{"date":"2021-12-10","current":5.037231,"twenty":6.070936,"median":8.60024,"eighty":10.227378,"marketCap":2290008000},{"date":"2021-12-17","current":4.86069,"twenty":6.054857,"median":8.564239,"eighty":10.190552,"marketCap":2208222000},{"date":"2021-12-24","current":4.916003,"twenty":6.052379,"median":8.514295,"eighty":10.154612,"marketCap":2235484000},{"date":"2021-12-31","current":5.144618,"twenty":6.047568,"median":8.504328,"eighty":10.145926,"marketCap":2344532000},{"date":"2022-01-07","current":5.164225,"twenty":6.042847,"median":8.4784,"eighty":10.143723,"marketCap":2344532000},{"date":"2022-01-14","current":5.093083,"twenty":6.038396,"median":8.458041,"eighty":10.124223,"marketCap":2317270000},{"date":"2022-01-21","current":5.380359,"twenty":6.023881,"median":8.434699,"eighty":10.073347,"marketCap":2453580000},{"date":"2022-01-28","current":5.034519,"twenty":6.017531,"median":8.407204,"eighty":10.033216,"marketCap":2290008000},{"date":"2022-02-04","current":5.156916,"twenty":6.014762,"median":8.39643,"eighty":10.012135,"marketCap":2344532000},{"date":"2022-02-11","current":5.206364,"twenty":6.007032,"median":8.358349,"eighty":9.99186,"marketCap":2371794000},{"date":"2022-02-18","current":5.240469,"twenty":5.997462,"median":8.310368,"eighty":9.985006,"marketCap":2399056000},{"date":"2022-02-25","current":4.989965,"twenty":5.989585,"median":8.200753,"eighty":9.95781,"marketCap":2290008000},{"date":"2022-03-04","current":4.928672,"twenty":5.979555,"median":8.170117,"eighty":9.938791,"marketCap":2262746000},{"date":"2022-03-11","current":4.876653,"twenty":5.973297,"median":8.123652,"eighty":9.894296,"marketCap":2235484000},{"date":"2022-03-18","current":4.717047,"twenty":5.960037,"median":8.070293,"eighty":9.868408,"marketCap":2153698000},{"date":"2022-03-25","current":5.194505,"twenty":5.957174,"median":8.005027,"eighty":9.829511,"marketCap":2371794000},{"date":"2022-04-01","current":4.531371,"twenty":5.948529,"median":7.973288,"eighty":9.81982,"marketCap":2317270000},{"date":"2022-04-08","current":4.649157,"twenty":5.946479,"median":7.953215,"eighty":9.804315,"marketCap":2371794000},{"date":"2022-04-14","current":4.707815,"twenty":5.940486,"median":7.879016,"eighty":9.79455,"marketCap":2399056000},{"date":"2022-04-22","current":4.802247,"twenty":5.934888,"median":7.843904,"eighty":9.78108,"marketCap":2399056000},{"date":"2022-04-29","current":4.825339,"twenty":5.919008,"median":7.698315,"eighty":9.768722,"marketCap":2371794000},{"date":"2022-05-06","current":4.410489,"twenty":5.9041,"median":7.676819,"eighty":9.755607,"marketCap":2399056000},{"date":"2022-05-13","current":4.541874,"twenty":5.900202,"median":7.615768,"eighty":9.747897,"marketCap":2426318000},{"date":"2022-05-20","current":6.290771,"twenty":5.897549,"median":7.514446,"eighty":9.724288,"marketCap":3407750000},{"date":"2022-05-27","current":7.303631,"twenty":5.895161,"median":7.434402,"eighty":9.709875,"marketCap":3952990000},{"date":"2022-06-02","current":7.264641,"twenty":5.89518,"median":7.334535,"eighty":9.703749,"marketCap":3952990000},{"date":"2022-06-10","current":10.869875,"twenty":5.895161,"median":7.322855,"eighty":9.700394,"marketCap":5888592000},{"date":"2022-06-17","current":10.755528,"twenty":5.895161,"median":7.322855,"eighty":9.700394,"marketCap":5806806000},{"date":"2022-06-24","current":10.662581,"twenty":5.895161,"median":7.322855,"eighty":9.700394,"marketCap":5779544000},{"date":"2022-06-30","current":10.731352,"twenty":5.895161,"median":7.322855,"eighty":9.700394,"marketCap":5806806000},{"date":"2022-07-08","current":10.820976,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5861330000},{"date":"2022-07-15","current":10.871399,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5834068000},{"date":"2022-07-22","current":10.864271,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5834068000},{"date":"2022-07-29","current":11.058353,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5943116000},{"date":"2022-08-05","current":11.082085,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5943116000},{"date":"2022-08-29","current":10.115403,"twenty":5.888507,"median":7.263276,"eighty":9.659414,"marketCap":6079426000},{"date":"2022-09-23","current":10.460916,"twenty":5.875785,"median":7.121577,"eighty":9.631568,"marketCap":6106688000},{"date":"2022-09-27","current":10.715865,"twenty":5.875785,"median":7.121577,"eighty":9.635273,"marketCap":6106688000},{"date":"2025-12-24","current":-18.447668,"twenty":4.982674,"median":6.211114,"eighty":10.220738,"marketCap":2368845453},{"date":"2026-01-02","current":-18.02665,"twenty":4.940407,"median":6.084014,"eighty":10.228734,"marketCap":2323893239},{"date":"2026-01-09","current":-17.992416,"twenty":4.931186,"median":6.014515,"eighty":10.205703,"marketCap":2325255428},{"date":"2026-01-16","current":-17.923631,"twenty":4.916421,"median":5.897664,"eighty":10.160138,"marketCap":2323893239},{"date":"2026-01-23","current":-17.982908,"twenty":4.885478,"median":5.797377,"eighty":10.160138,"marketCap":2329341993},{"date":"2026-01-30","current":-17.744046,"twenty":4.875244,"median":5.725499,"eighty":10.160138,"marketCap":2308909168},{"date":"2026-02-06","current":-16.811585,"twenty":4.866613,"median":5.578062,"eighty":10.122459,"marketCap":2193123163},{"date":"2026-02-13","current":-19.892571,"twenty":4.857721,"median":5.514388,"eighty":9.398557,"marketCap":2609952782}],"updateTime":1771160135886},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03378\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1151725131","title":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378) Announces EGM Poll Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1151725131","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151725131?lang=en_us&edition=fundamental","pubTime":"2026-02-12 18:06","pubTimestamp":1770890768,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) held its Extraordinary General Meeting on February 12, 2026, at the company’s conference room in Wuhan, Hubei Province. Shareholders...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":0},{"id":"2610496449","title":"Hanx Biopharmaceuticals (Wuhan) Co. Ltd. held extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2610496449","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610496449?lang=en_us&edition=fundamental","pubTime":"2026-02-12 17:42","pubTimestamp":1770889337,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals  Co. Ltd. held an extraordinary general meeting on February 12, 2026. During the meeting, shareholders considered and approved a proposal to grant the Board a general mandate to repurchase H Shares during the relevant period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL9dyjwW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","BK1535","03378"],"gpt_icon":0},{"id":"1198068857","title":"Hanx Biopharmaceuticals (3378) Announces Board and Committee Composition","url":"https://stock-news.laohu8.com/highlight/detail?id=1198068857","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198068857?lang=en_us&edition=fundamental","pubTime":"2026-02-08 18:23","pubTimestamp":1770546197,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) released an announcement on February 8, 2026, detailing the composition of its Board of Directors. The Board consists of four executive...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":0},{"id":"2609752115","title":"Hanx Biopharmaceuticals Files Director List with HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2609752115","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609752115?lang=en_us&edition=fundamental","pubTime":"2026-02-08 18:04","pubTimestamp":1770545087,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals  Co. Ltd. has filed an updated list of directors and their roles with the Hong Kong Stock Exchange. The Board is chaired by Dr. Zhang Faming, who also serves as Chairperson of the Nomination Committee. Other executive directors include Dr. Henry Qixiang Li , Mr. Liu Min, and Ms. Xiao Jieyu . The non-executive director is Dr. Li Jian. Independent non-executive directors are Dr. Bi Honggang , Mr. Chen Qifeng , Mr. Wong Sai Hung , and Dr. Zhang Qiongguang . The company reports three board committees: Audit, Nomination, and Remuneration.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Serv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260208:nNDL9GGGmR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","BK1535","03378"],"gpt_icon":0},{"id":"2608647293","title":"Hanx Biopharmaceuticals Enrolls, Doses First Patient in Tumor Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2608647293","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608647293?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:15","pubTimestamp":1770210953,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals (HKG:3378) completed the first patient enrollment and dosing in a phase I clinical trial of HX111, according to a Wednesday Hong Kong bourse filing.The drug is being tested for the treatment of relapsed/refractory lymphoma and solid tumors.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"1130563360","title":"Hanx Biopharmaceuticals (3378) Announces First Patient Dosing in HX111 Phase I Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1130563360","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130563360?lang=en_us&edition=fundamental","pubTime":"2026-02-04 21:04","pubTimestamp":1770210246,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the “Company”) has initiated the Phase I clinical trial of HX111, an independently developed OX40-targeting antibody-drug conjugate candidate for the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":0},{"id":"1177045690","title":"HANXBIO-B (03378): First Patient Dosed in HX111 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1177045690","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177045690?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:56","pubTimestamp":1770209778,"startTime":"0","endTime":"0","summary":"HANXBIO-B (03378) has announced the initiation of a Phase I clinical trial for its self-developed drug candidate, HX111, an OX40-targeting antibody-drug conjugate (ADC). The trial, which focuses on...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378","BK1173","BK1535"],"gpt_icon":0},{"id":"1188505220","title":"HANXBIO-B (03378) Announces Reassignment of Xiao Jieyu from Non-Executive to Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=1188505220","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188505220?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:53","pubTimestamp":1770209597,"startTime":"0","endTime":"0","summary":"HANXBIO-B (03378) has announced that, due to work adjustments, Ms. Xiao Jieyu has been reassigned from a Non-Executive Director to an Executive Director, effective from February 8, 2026. Following...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","03378","BK1535"],"gpt_icon":0},{"id":"2608361919","title":"Hanx Biopharmaceuticals Doses First Patient in Phase I Trial of OX40-Targeted ADC HX111","url":"https://stock-news.laohu8.com/highlight/detail?id=2608361919","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608361919?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:49","pubTimestamp":1770209374,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals  Co. Ltd. announced the initiation of a Phase I clinical trial for HX111, an OX40-targeting antibody-drug conjugate  developed for the treatment of relapsed or refractory lymphoma and solid tumors. The company has completed the first patient enrollment and dosing in this trial. HX111 is the first OX40-targeted ADC globally to publicly enter the clinical stage. According to the announcement, there are currently no results presented, as the study has recently begun.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 04, 2026, a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL5M3BGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378","BK1173","BK1535"],"gpt_icon":0},{"id":"2608736152","title":"Hanx Biopharmaceuticals (Wuhan) Co Ltd - Xiao Jieyu Re-Designated as Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2608736152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608736152?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:44","pubTimestamp":1770209099,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z00NF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"2608696361","title":"Hanx Biopharmaceuticals (Wuhan) - Zhang Hui Resigned as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2608696361","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608696361?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:44","pubTimestamp":1770209099,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nFWN3Z00NF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1173","BK1535","03378"],"gpt_icon":0},{"id":"2608616923","title":"Hanx Biopharmaceuticals Appoints Xiao Jieyu as Executive Director and CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2608616923","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608616923?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:44","pubTimestamp":1770209098,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals  Co. Ltd. announced several management changes, including the re-designation of Ms. Xiao Jieyu from non-executive director to executive director effective 8 February 2026. The company also announced the resignation of its joint company secretary, chief financial officer, secretary of the board, and vice general manager, as well as the appointment of a new chief financial officer and secretary of the board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 04, 2026, and is solely responsible for the information contained ther","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nNDL1Cvts8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","BK1535","03378"],"gpt_icon":0},{"id":"2606731397","title":"Hanx Biopharmaceuticals Proposes General Mandate to Repurchase H Shares at Upcoming EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2606731397","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606731397?lang=en_us&edition=fundamental","pubTime":"2026-01-28 01:20","pubTimestamp":1769534411,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals  Co. Ltd. has proposed granting a general mandate to repurchase H shares, which will be put to a shareholder vote at an extraordinary general meeting scheduled for February 12, 2026. Shareholders are advised to consult their professional advisers regarding how to vote on the proposal.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanx Biopharmaceuticals  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL3McFyx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"1162715402","title":"Hanx Biopharmaceuticals (3378) Announces Extraordinary General Meeting Agenda","url":"https://stock-news.laohu8.com/highlight/detail?id=1162715402","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162715402?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:45","pubTimestamp":1769521521,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) has released details for an Extraordinary General Meeting (EGM) scheduled for 10:00 a.m. on Thursday, February 12, 2026. The meeting will...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":0},{"id":"1147175269","title":"Hanx Biopharmaceuticals (3378) Announces Proposal for H Share Repurchase Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1147175269","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147175269?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:44","pubTimestamp":1769521493,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) released an announcement regarding an upcoming extraordinary general meeting (EGM) scheduled for Thursday, February 12, 2026, at 10:00...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":0},{"id":"1186334181","title":"HANXBIO-B Announces Conclusion of Stabilization Period, No Stabilization Actions Taken, and Over-Allotment Option Lapses","url":"https://stock-news.laohu8.com/highlight/detail?id=1186334181","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186334181?lang=en_us&edition=fundamental","pubTime":"2026-01-26 09:20","pubTimestamp":1769390440,"startTime":"0","endTime":"0","summary":"HANXBIO-B (03378) has issued an announcement stating that the stabilization period relating to the global offering concluded on Saturday, January 17, 2026, which was the 30th day after the deadline...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","03378","BK1535"],"gpt_icon":0},{"id":"1165644116","title":"Hanx Biopharmaceuticals (3378) Announces End of Stabilization Period and Lapse of Over-allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1165644116","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1165644116?lang=en_us&edition=fundamental","pubTime":"2026-01-23 22:04","pubTimestamp":1769177054,"startTime":"0","endTime":"0","summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (Stock Code: 3378) released an announcement dated January 23, 2026, indicating that the stabilization period for the Global Offering ended on January 17,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03378"],"gpt_icon":0},{"id":"1152283674","title":"HANXBIO-B (03378): Stabilization Period Concludes, No Price-Stabilizing Actions, and Over-Allotment Option Lapses","url":"https://stock-news.laohu8.com/highlight/detail?id=1152283674","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152283674?lang=en_us&edition=fundamental","pubTime":"2026-01-23 21:56","pubTimestamp":1769176600,"startTime":"0","endTime":"0","summary":"HANXBIO-B (03378) announced that the stabilization period relating to the global offering concluded on Saturday, January 17, 2026, which was the 30th day after the deadline for submitting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"1167947014","title":"Stock Track | HANXBIO-B Plummets 13.46% Intraday Amid Financial Losses and Lack of Commercialized Products","url":"https://stock-news.laohu8.com/highlight/detail?id=1167947014","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167947014?lang=en_us&edition=fundamental","pubTime":"2025-12-29 14:00","pubTimestamp":1766988021,"startTime":"0","endTime":"0","summary":"HANXBIO-B (03378) saw its stock price plummet by 13.46% during intraday trading on Monday, hitting a fresh low of HK$15.05. This decline represents a drop of over 50% from its initial public offering...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["03378"],"gpt_icon":1},{"id":"1154910467","title":"HANXBIO-B (03378) Plummets Over 13%, Halved from IPO Price with Market Cap Around HK$2 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1154910467","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154910467?lang=en_us&edition=fundamental","pubTime":"2025-12-29 13:58","pubTimestamp":1766987900,"startTime":"0","endTime":"0","summary":"HANXBIO-B (03378) plunged more than 13%, hitting a fresh low of HK$15.05 intraday, which represents a decline of over 50% from its initial public offering price of HK$32. As of writing, the stock was...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1173","03378","BK1535"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}